Several clinical trials are currently being conducted on patients with R/R CD30+ lymphomas, including some ATL patients under a pilot study in patients with R/R disease (NCT01703949), and a phase 2 study on patients with R/R CD30-low mature T-cell lymphomas (Hermine et al., 2018). Here, TNFRSF8 is linked to T-cell non-Hodgkin lymphoma.